Generalized Anxiety Disorder Market would generate over $7.4 billion in revenues at a CAGR of over 2.5% over the forecast period 2018-2023

According to the new market research report by IndustryARC titled “Generalized Anxiety Disorder Market: By Therapeutics Type (Antidepressant, Benzodiazepines, Others (Buspirone)) & Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2018-2023)”, the market is estimated to grow at 2.5% CAGR to reach $7.5 billion by 2023.

North America continues to lead the market share during 2018-2023.
North America held the major share in global Generalized Anxiety Disorder Market, followed by Europe and Asia-Pacific region in terms of revenue. In North America, Mexico is the leading country with 2.5% CAGR followed by Canada and the U.S. with 2.0% and 1.5% CAGR respectively. In Canada, the number of depression cases is likely to increase with the adoption of sedentary lifestyles. This has brought forward the newfound demand for the development of therapeutics and is more likely to have a positive impact on the demand and growth for generalized anxiety disorder market.

The developments in mental health-care services and raising awareness towards anxiety disorders are responsible for the increase in the diagnosis of GAD in this region. The growing geriatric population is increasing the anxiety diagnosis rates in Mexico, thus directly boosting the demand for physiotherapies such as Cognitive Behavior Therapy (CBT) and GAD medication.

The sedentary lifestyle and stressful work environments are the major factors for the growing incidence of anxiety disorders in the U.S. According to Anxiety and Depression Association of America (ADAA), nearly 6.8 million people accounting to 3.1% of total population are affected by GAD every year. Moreover, the approval of several drugs including antidepressant drugs such as Paroxetine and Escitalopram, and benzodiazepine sedatives such as

Alprazolam and Clonazepam are promising for the growth of therapeutic drugs in the U.S.
Anxiety and depressive disorders emerged as the two most common psychiatric illnesses across the globe. According to WHO, Brazil has the highest prevalence of anxiety disorders in the world and the country ranks fifth in depression disorders. The Asia-Pacific region is estimated to witness the fastest growth rate to reach $1.8 billion with a CAGR of 3.8 by 2023. It is expected to register healthy growth especially from India and China owing to the rising healthcare expenditure coupled with the growing number of geriatric population with depression, anxiety, and panic disorders. The transition of psychiatric services in Japan towards the adoption of standardized diagnostic criteria and advanced antidepressant drugs such as selective serotonin, reuptake inhibitors are also increasing the prevalence of GAD.

Selected Type of Value Chain Analysis done in the full Report:
• The value chain analysis deals with the comprehensive evaluation of each activity involved in the processing of any product/service and finally delivering it to the end-users. Each stage across the value chain of a product or service is associated with creating some sort of monetary value. The value chain analysis can offer the company a chance to examine every activity across the value chain and identify the steps where elimination or modification is essential.
• The value chain of the generalized anxiety disorder market involves various stages such as research and development, clinical trials, regulatory agencies, distributors and end users.
• Initially, the prototype is manufactured based on R&D and undergoes various phases of examination by regulatory bodies. It will get approved once it passes all the stages. These approved generalized anxiety disorders drugs are manufactured in bulk and are distributed directly or indirectly to end users.

Excerpts on Market Growth Factors Mentioned in the Full Report:
1. Generalized anxiety disorder market is experiencing growth globally owing to the rising instances of depression and global anxiety disorders among working-class population due to extreme stress and busy lifestyles.
2. Aggregating healthcare expenditure coupled with the increasing number of FDA approved drugs for treating anxiety disorders is providing opportunities for manufacturers to invest in research and product development of these drugs and expand their product portfolio.
3. Increasing stress and sedentary lifestyle is increasing the number of patients suffering from GAD and thus, driving the market growth globally.
4. Technological advancement in the pharmaceutical industry is slated to provide a significant opportunity to the generalized anxiety disorder market.
5. Additionally, increasing public and private partnerships in the healthcare sector for R&D of generalized anxiety disorder drugs offers opportunity in the coming future for the GAD market.

To Access/Purchase the full report, Please browse the link below:
https://industryarc.com/Report/15869/generalized-anxiety-disorder-market.html

Key Players of the Generalized Anxiety Disorder Market:
Pfizer, Inc. and Eli Lilly and Company are analyzed to be the dominant players of the Generalized Anxiety Disorder market. The top 5 companies constitute more than 50% share in the total market globally. Acquisitions and partnerships are the key strategies adopted by companies to enhance their market share.

Companies Cited/Referred/Interviewed:
Abbott Laboratories, Allergan plc, Bristol-Myers Squibb Company, F-Hoffmann-La Roche, GlaxoSmithKline plc, Noven Pharmaceuticals Inc, Shionogi and company, Sumitomo Dainippon Pharma Co., Ltd.

Generalized Anxiety Disorder Market Report is Segmented as indicated below.
• Generalized Anxiety Disorder Market By Therapeutics Type:
1. Antidepressants

1.1 Selective Serotonin Reuptake Inhibitors (SSRI)
1.2 Serotonin Norepinephrine Reuptake Inhibitors (SNRI)

2. Benzodiazepines

2.1 Alprazolam
2.2 Chlordiazepoxide
2.3 Diazepam
2.4 Lorazepam

3. Others (Buspirone)
• Generalized Anxiety Disorder Market By Geography ( Covers 14+ Countries )
• Generalized Anxiety Disorder Market Entropy
• Company Profiles
• Appendix: Abbreviations, Sources, Research Methodology, Bibliography, Compilation of Experts, Disclaimer.

What can you expect from the report?
The Generalized Anxiety Disorder Market Report is Prepared with the Main Agenda to Cover the following 20 points:
• Market Size by Product Categories
• Market trends
• Manufacturer Landscape
• Distributor Landscape
• Pricing Analysis
• Top 10 End user Analysis
• Product Benchmarking
• Product Developments
• Mergers & Acquisition Analysis
• Patent Analysis
• Demand Analysis (By Revenue & Volume)
• Country level Analysis (15+)
• Competitor Analysis
• Market Shares Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Strategic Analysis
• Current & Future Market Landscape Analysis
• Opportunity Analysis
• Revenue and Volume Analysis

Any other major customizations can be discussed with our team, we can provide a separate quote based on your requirements. You can drop in an e-mail to sales@industryarc.com to discuss more about our consulting services.

Media Contact:
Mr. Venkat Reddy
Sales Manager
Email 1: sales@industryarc.com
Or Email 2: venkat@industryarc.com
Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC:
IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC
Plot No. 56, HUDA Techno Enclave LP Towers, Opp. Melange Tower, Madhapur, Hyderabad, Telangana 500081

sales@industryarc.com

+1614-588-8538

This release was published on openPR.